GENERAL ORTHOPAEDICS
Fenofibrate produces a reduction in amputation events in type II diabetics
Lancet. 2009 May 23;373(9677):1780-89795 patients with type II diabetes were randomized to receive daily treatment with 200 mg of fenofibrate or equivalent placebo treatment. This study examined the effect of a long-term lipid-lowering treatment on occurrence of amputation and reduction of adverse outcomes of the macro- and micro-vasculature. At 5 year follow-up, fenofibrate produced a reduction in non-traumatic amputations observed in type II diabetics.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
